What is 南京维立志博生物科技有限公司's contact information?

南京维立志博生物科技有限公司's contact information: +862583378099.

How many employees does 南京维立志博生物科技有限公司 have?

南京维立志博生物科技有限公司 has 6 employees.

What industry does 南京维立志博生物科技有限公司 belong to?

南京维立志博生物科技有限公司 is in the industry of: Pharmaceuticals, Biotechnology, Healthcare.

What are 南京维立志博生物科技有限公司's official social media profiles?

南京维立志博生物科技有限公司 Linkedin Page

What tech stack does 南京维立志博生物科技有限公司 use?

Some of the popular technologies that 南京维立志博生物科技有限公司 uses are: Font Awesome, Google Font API, jQuery, Chinese.

What are 南京维立志博生物科技有限公司's office addresses?

南京维立志博生物科技有限公司 has a known office at the following address: 南京高新技术产业开发区新锦湖路3-1号中丹生态生命科学产业园一期A座951-6室南京, 江苏 210000, Cn.

What is 南京维立志博生物科技有限公司's open headcount?

南京维立志博生物科技有限公司 has no job postings yet.

What is the number of ad campaigns for 南京维立志博生物科技有限公司?

南京维立志博生物科技有限公司 has no advertisements yet.

What is the number of recent news articles about 南京维立志博生物科技有限公司?

南京维立志博生物科技有限公司 has 20 news articles.

南京维立志博生物科技有限公司 - Pubrio Company Profile & Intent

南京维立志博生物科技有限公司

China · Biotechnology

Pharmaceuticals

Biotechnology

Healthcare

LeadsBioLabs specializes in delivering high-quality leads to biotech companies, helping them connect with potential clients and partners. Our services are tailored to the unique needs of the biotech industry, ensuring that companies can focus on their core research and development efforts.

Company Insights

prnasia.com · launches · 2 days ago

Open news

Leads Biolabs begins Phase II trial for ESCC treatment

Leads Biolabs starts Phase II trial of Opamtistomig for esophageal squamous cell carcinoma, aiming to improve treatment outcomes with innovative bispecific antibody approach.

Nmpa-National Medical Products Administration

Gigagreen Project

南京维立志博生物科技有限公司

Iarc - International Agency For Research On Cancer / World Health Organization

Fda

prnasia.com · recognized_as · 2025-12-08

Open news

Leads Biolabs presents promising LBL-034 results at ASH

Leads Biolabs presented Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody, at ASH 2025, showing favorable safety and strong anti-tumor activity in relapsed/refractory multiple myeloma patients.

南京维立志博生物科技有限公司

prnasia.com · recognized_as · 2025-11-04

Open news

LBL-034 and LBL-076 research to be presented at ASH 2025

Leads Bio's LBL-034 and LBL-076 research for multiple myeloma treatment will be presented at the 67th ASH Annual Meeting in 2025, including oral and poster presentations.

American Society Of Hematology

南京维立志博生物科技有限公司

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin option investors bet on downside despite price rise

Bitcoin ETF and crypto-holding firms are buying put options to hedge against potential price drops below $60,000, despite recent price increases.

Coindesk

Deribit

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin's 'Death Cross' Appears: Future Trends?

Bitcoin chart shows 'death cross' pattern, historically preceding major price drops. Despite this, ETFs see $1 billion inflow and long-term investors continue accumulating.

Coindesk

Upbit Singapore

coinreaders.com · launches · one week ago

Open news

JPMorgan: Crypto Market Structure Act likely to pass mid-year

JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.

Coindesk

J.P. Morgan

Get full access to view complete information

1 - 20 of 20

Frequently Asked Questions Regarding 南京维立志博生物科技有限公司

Company Overview

2013

Founded

Biotechnology

Industry

China

Location

8,236,044

Ranking

6 employees

Size

Similar Companies

Get full access to view complete information